Background Real-world data on the impact of advances in risk-adjusted management on the
outcome of patients with pulmonary embolism (PE) are limited. Methods To investigate …

Abstract INTRODUCTION Pulmonary Embolism (PE) is the third most common
cardiovascular condition. The American Society of Hematology recommends the use of …

This chapter provides insight into the clinical decision-making process when selecting an
outpatient anticoagulation agent and length of therapy following acute pulmonary embolism …

Background: Intravenous unfractionated heparin (UFH) is commonly used for therapeutic
anticoagulation in patients with acute pulmonary embolism (PE), which requires close …

We wish to clarify the dosing recommendations of lowmolecular-weight heparin (LMWH) in
the treatment of acute pulmonary embolism (PE) as discussed by Kearon et al1 in an issue …

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism.
Summary document prepared by the Czech Society of Cardiology × Close The Infona portal …

2. Methods The design of the RIETE has been reported previously [6]. In brief, RIETE is an
ongoing, prospective multicenter multinational cohort study of patients with objectively …

Background In patients with a first, unprovoked venous thromboembolism (VTE), the optimal
duration of anticoagulant therapy (AT) is controversial due to tightly balanced risks and …

Background Occurrence of chronic thromboembolic disease (CTED) after 3 or 6 months of
standard and effective anticoagulation is not uncommon in patients with acute pulmonary …

Background Evidence-based clinical practice guidelines define initial management of acute
pulmonary embolism (PE) according to risk stratification for early death. Aims The aims of …